ClinConnect ClinConnect Logo
Search / Trial NCT05608525

Upper Limb tDCS in Chronic Stroke Patients (NOURISH)

Launched by NATIONAL UNIVERSITY HOSPITAL, SINGAPORE · Nov 1, 2022

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Stroke Motor Recovery Transcranial Direct Current Stimulation Corticospinal Excitability Neuromodulation

ClinConnect Summary

The NOURISH clinical trial is studying a treatment called Transcranial Direct Current Stimulation (tDCS) to see if it can help improve movement in the arms of people who have had a stroke. The trial is looking for participants aged 21 to 80 who have had their first stroke between 6 months and 2 years ago and have some difficulty using their affected arm. This study will involve about 51 participants, who will be divided into three groups. Two groups will receive actual tDCS treatment while the third group will receive a "sham" treatment, which means they will get a very short, non-effective version of the stimulation.

Participants will attend daily sessions for about a month, where they will receive tDCS for 20 minutes along with a standard therapy called GRASP, which focuses on improving arm function. Researchers will assess how well the treatment works by measuring various aspects of arm movement and brain activity before, immediately after, and one month after the treatment. It's important to note that individuals with certain medical conditions, like pregnancy, epilepsy, or major depression, will not be eligible to participate. This trial is currently recruiting participants, and those who join can expect to contribute valuable information that could help improve recovery for stroke patients in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 21-80 years old;
  • First ever stroke, 6 months to 2 years after stroke onset;
  • ARAT≤42
  • Exclusion Criteria:
  • 1. Pregnancy;
  • 2. Any metal implants inside the body that are contraindications of MRI scan;
  • 3. cardiac pacemakers;
  • 4. History of epilepsy;
  • 5. Sensorimotor disturbance due to other causes other than stroke;
  • 6. Claustrophobia;
  • 7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;
  • 8. Major depression and a history of psychotic disorders;
  • 9. Terminal diagnosis with life expectancy \<=1 year. Any metal implants inside the body that are contraindications of MRI scan;
  • 3. cardiac pacemakers; 4. History of epilepsy; 5. Sensorimotor disturbance due to other causes other than stroke; 6. Claustrophobia; 7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina; 8. Major depression and a history of psychotic disorders; 9. Terminal diagnosis with life expectancy \<=1 year.

About National University Hospital, Singapore

National University Hospital (NUH) in Singapore is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, NUH emphasizes a multidisciplinary approach, integrating cutting-edge medical research with high-quality patient care. The hospital collaborates with various stakeholders, including academic institutions and industry partners, to explore new therapies and improve treatment outcomes across a wide range of medical disciplines. Committed to ethical standards and patient safety, NUH plays a pivotal role in shaping the future of medicine in Singapore and beyond.

Locations

Singapore, , Singapore

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Effie Chew, MBBS

Principal Investigator

National University Hospital, Singapore

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials